TUBA OĞUZ, ARDA KEBAPCI, NEŞE AYŞİT
Acta Pharmaceutica Sciencia - 2025;63(2):367-380
Breast cancer is a prevalent malignancy that requires tailored treatments. Cisplatin, a platinum-based chemotherapy agent, is widely used for its anti-proliferative and pro-apoptotic properties. Understanding its molecular mechanisms is crucial for optimizing its efficacy. We investigated cisplatin’s effect on the EMT6 breast cancer cell line across various doses and durations. Using MTT assay and qPCR, we examined cell survival and gene expressions of PTEN, MAPK, NFEL2L2, and Survivin after 24 h and 48 h of cisplatin treatments. The highest viability was at 5 µM after 24 h and at 1 and 5 µM after 48 h, with significant decreases at higher concentrations. Significant changes were observed in MAPK, NFEL2L2 and Survivin, while PTEN remained unaffected. Notably, Survivin was upregulated at lower doses, while NFEL2L2 and MAPK showed no significant changes. Our findings indicate that cisplatin induces apoptosis and alters gene expression in a dose-dependent manner, providing insights into its molecular mechanisms in EMT6 cells.
